Bisoprolol fumarate and hydrochlorothiazide have been used individually and in combination for the treatment of hypertension. They combine a synthetic beta1-selective (cardioselective) adrenoceptor blocking agent (bisoprolol fumarate) and a benzothiadiazine diuretic (hydrochlorothiazide). The antihypertensive effects of these agents are additive; hydrochlorothiazide significantly increases the antihypertensive effect of bisoprolol fumarate.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C07BB07 | Bisoprolol and thiazides | C Cardiovascular system → C07 Beta blocking agents → C07B Beta blocking agents and thiazides → C07BB Beta blocking agents, non-selective, and thiazides |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZIAC Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
